Tags : ATTRACTION-3 Study

ONO Pharmaceutical Reports Results of Opdivo (Nivolumab) in P-III ATTRACTION-3

Shots:  The P-III ATTRACTION-3 study involves assessing of Opdivo (involumab, IV) vs CT (docetaxel/paclitaxel) in patients with unresectable advanced or recurrent esophageal cancer or intolerant to fluoropyrimidine + PT-based drug The study demonstrated in meeting 1EPs with superiority in overall survival of Opdivo vs CT Opdivo(Nivolumab) is a PD-1 immune checkpoint inhibitor targeted against cancer […]Read More